Stocks Listing
FATE

Fate Therapeutics, Inc.

Share
FATE
$23.26 1.77%Last Updated Oct 06 2022 07:56 PM
1D Low / 1D High
Low:$22.94
High:$23.89
1D
1.77%
5D
1.97 %
30D
10.5 %
BulletPurple
Market Cap
$2,229,870,592
1.29 %
2.2 B
BulletBlue
Volume 1D
677,678
-
677.7 K
BulletOrange
Circulating Supply
95,887,792 FATE
95.9 M

Price Chart

1D
5D
1M
6M
YTD
1Y
MAX
About

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors, as well as ProTmune for the treatment of hematologic malignancies and rare genetic disorders. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Historical data

1D
5D
1M
6M
1Y
MAX
Day
Open - Close
Low/High
Volume
Market Cap
Show More
Market Status
Closed
NGM
NASDAQ Stock Exchange
USA
Opens in
13 hours, 59 minutes
Working Hours
Mon-Fri, 01:30 PM - 08:00 PM
Timezone
GMT+0